| answer text |
<p>Healthy vaccine markets are essential to provide adequate supplies of vaccines
at affordable prices for poor countries. This, in turn, improves availability and
drives demand for immunisation. The UK supports healthy vaccine market competition
through our investment in Gavi, the Vaccine Alliance.</p><p> </p><p>A core part of
Gavi’s mission is to promote competition and reduce the cost of vaccines. Gavi now
supports 17 manufacturers to provide critical vaccines at a lower cost. Many of these
manufacturers are now based in low and middle income countries. This has successfully
generated over US$764 million in cost savings in 2017 alone and has reduced the cost
of immunising a child by 17% since 2016.</p><p> </p><p>The UK also supports Gavi’s
Advanced Market Commitment for Pneumococcal Vaccines (AMC), an innovative approach
to fostering market competition. By incentivising investment in research and development
in the pneumococcal vaccine, the AMC has expanded manufacturing capacity and helped
develop a healthy pipeline for vaccine production. This has helped enable 143 million
children in 58 countries to be vaccinated against severe pneumonia.</p>
|
|
